Table 1 Main patient characteristics
Age at diagnosis, years | 65 (48–77) |
PSA at diagnosis, ng/ml | 7.8 (4.0–81.0) |
BMI at diagnosis, kg/m2 | 26.3 (17.4–34.6) |
Prostate volume, ml | 41.2 (22.4–103.9) |
Tumor percentage, % | 10.2(2.3–52.9) |
Cancer familiarity, | |
neg | 6 (5.7 %) |
pos | 100 (94.3 %) |
DRE, | |
neg | 71 (67.6 %) |
pos | 34 (32.4 %) |
GS at biopsy, | |
6 | 31(29.5 %) |
7(3 + 4) | 29(27.6 %) |
7(4 + 3) | 21(20.0 %) |
8 | 16(15.2 %) |
9 | 8(7.6 %) |
Lesions at MRI, | |
1 | 31 (53.4 %) |
2+ | 27 (46.6 %) |
GS at surgery, | |
6 | 4(3.8 %) |
7(3 + 4) | 37(37.4 %) |
7(4 + 3) | 37(37.4 %) |
8 | 15(15.2 %) |
9 | 6(6.1 %) |
Margins, | |
neg | 53 (50.0 %) |
pos | 53 (50.0 %) |
Capsule involvement, | |
neg | 25 (23.6 %) |
pos | 81 (76.4 %) |
Neural involvement, | |
neg | 8 (7.5 %) |
pos | 98 (92.5 %) |
Vascular involvement, | |
neg | 65 (68.4 %) |
pos | 30 (31.6 %) |
pT2 | 9 (8.5 %) |
pT3a | 83 (78.3 %) |
pT3b | 14 (13.2 %) |
pN0 | 69 (79.3 %) |
pN+ | 18 (20.7 %) |
uPSA, ng/ml 1/3/6/9/12 months | 0.010 (0–1.15)/0.018 (0–0.67)/0.051 (0.01–0.52)/0.100 (0.01–0.56)/0.154 (0–0.89) |
[−2]proPSA, pg/ml 1/3/6/9/12 months | 0.22 (0–2.14)/0.57 (0–2.84)/0.89 (0–3.97)/1.25 (0.03–3.72)/1.38 (0–4.86) |